The presence and number of GBM stem cells (GSCs) is one of the major factors which determine aggressiveness and treatment resistance of the tumor bulk, and surface expression of CD133 (PROM1) is regarded as a putative marker for GSCs [24]. The gene discussed is PROM1; the disease is neoplasm.